P2, N=20, Not yet recruiting, Centre Hospitalier Universitaire de Nice | Trial completion date: Aug 2024 --> Aug 2025 | Initiation date: Aug 2024 --> Nov 2024 | Trial primary completion date: Aug 2024 --> Aug 2025
13 days ago
Trial completion date • Trial initiation date • Trial primary completion date
cAMP, via activation of both PKA and Epac, is essential for GLP1R`s anti-inflammatory signaling in cardiac cells and that cAMP levels crucially regulate the anti-inflammatory efficacy of GLP1R agonists in the heart. Strategies that elevate cardiac cAMP levels, such as PDE4 inhibition, may potentiate the cardiovascular, including anti-inflammatory, benefits of GLP1R agonist drugs.
We describe a case of M.tuberculosis reactivation shortly after commencement of apremilast for psoriasis. We are recommending clinicians perform LTBI risk assessment in all patients, and appropriate LTBI screening in select populations prior to apremilast initiation.
The combination of vitamin D and crisaborole significantly reduces inflammation and epidermal hyperkeratosis in a mouse model of allergic contact dermatitis, demonstrating superior therapeutic efficacy compared to either treatment alone. This suggests that the combined therapy could be a promising approach for the prevention and treatment of allergic contact dermatitis.
P1, N=28, Active, not recruiting, Wake Forest University Health Sciences | Trial completion date: Dec 2024 --> Jul 2025 | Trial primary completion date: Aug 2024 --> Jan 2025
2 months ago
Trial completion date • Trial primary completion date • Adherence
P1, N=84, Not yet recruiting, Wake Forest University Health Sciences | Trial completion date: Feb 2025 --> Oct 2025 | Trial primary completion date: Dec 2024 --> Mar 2025
3 months ago
Trial completion date • Trial primary completion date • Adherence
P2, N=120, Recruiting, VA Office of Research and Development | Trial completion date: Dec 2024 --> Dec 2025 | Trial primary completion date: Jun 2024 --> Jun 2025
3 months ago
Trial completion date • Trial primary completion date
Additionally, the knockdown of AHR or NRF2 abolished the difamilast-induced sST2 production. These results indicate that difamilast treatment produces sST2 via the AHR-NRF2 axis, contributing to improving AD symptoms by inhibiting IL-33 activity.